On June 13, 2023 Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported that it will host an R&D Event to discuss the pipeline expansion and the evolution of its end-to-end platform on Tuesday, June 20, 2023, at 10:00 am ET (Press release, MediGene, JUN 13, 2023, View Source [SID1234632673]). A live Q&A session will follow the formal presentations and discussions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s leadership team will be discussing the evolution of Medigene’s end-to-end platform and their exciting pipeline expansion into neoantigens with programs targeting multiple KRAS (Kirsten rat sarcoma viral oncogene homologue) mutations and HLAs (human leukocyte antigens), focused on developing differentiated, best-in-class T cell receptor-engineered T cell (TCR‑T) therapies for multiple solid tumor indications.

Attendees are invited to listen to the presentations and discussions exploring the unmet needs in the treatment of solid tumors.

Full details for the webcast and registration are as follows:

Date: June 20, 2023
Time: 10:00 am ET
Location: Virtual
Webcast registration: View Source

Following the call, an archived webcast will also be accessible on the Investors & Media section of the Medigene website View Source